🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ICYMI. EULAR & ACR have developed new risk stratification criteria for rheumatoid arthritis (RA). The criteria have been developed for people with arthralgia in secondary care who are considered at risk for RA. Learn more! #RA #rheumatoidarthritis #rheum

#EULAR new #RA #recommendations J Smolen presents justification for #MTX +#glucocorticoids at onset do you agree? Diff from #ACR #EULAR #Recommendations II #EULAR2025 Dr. John Cush

URAT1 inhibitors look like the way to go in Gout! Presented in multiple abstracts at #EULAR2025 Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300 Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302 Ph 2b RCT of SAP-001 Refractory Gout +/-

from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE So far so good but how far do we need to go? #EULAR2025 Dr. John Cush LB0007

#EULAR2025 EULAR update #Recommendations #Rheumatoid #Rx prof Smolen subtle diff between former guidelines MTX+GC 👇 D/C GCs rapidly 👇 If inadequate response 👇 Other csDMARDs are OUT ❎ ✅go to bDMARD or tsDMARD* TsDMARD after safety assessed Dr. John Cush RecommendatnII

FIBRONEER-ILD Ph3 PD4B inhibitor Nerandomilast 1100+ pts, 320+ w/ SARD-ILD wk52 FVC relative reduction of decline 9 mg bid 43% 18 mg bid 39% vs. PBO HR 0.56 time to first acute exacerbation of ILD, hospitalisation for resp cause or death in higher dose group 11%

APEX study Ph3 RCT Guselkumab In BioNaive active PsA w/ erosions>=2 wk 24 ACR20 GUS Q4W 67% Q8W 68% vs PBO 47% Less Rx progression in both Q4W & Q8W vs. PBO #EULAR2025 Dr. John Cush LB0010

The relation between RA, comorbidities and presenteism NRAS survey 891 RA pts 75% had at least one comorbidity Absenteeism more likely if One OR = 1.68 or Two OR = 2.26 comorbid conditions In particular Anxiety OR = 2.39 Depression OR = 1.75 Osteoarthritis OR = 1.85 Back

Why do Rheumatologists shift to private practice? Are there gender based differences? A survey of 100+ European rheumatologists Female 🚺 rheumatologists: Leave hospital earlier At a lower hierarchical level Reasons for leaving: nightshifts unfair promotion decisions

What do we do when we see Rx signed of CPPD in RA pts? Do these pts have different trajectory? Rx Retro study 388 patients RA 18% at least one sign CPPD ns diff between seeonegative and seropositive pts RA+CPPD group was -older -higher comorbidity score -more likely to be

Climate Change Impacts #Rheumatology Care Taking HEAT 🥵 causes: 🔺️⬆️ Hospitalisations 🔺️Renal failure ⚠️ NSAIDs 🔺️Flooding: no access to healthcare 🔺️New Infectious diseases mimics RMDs: Zika... 🔺️Insecurities for drug storage and transportation #EULAR2025 Dr. John Cush

Conveying the struggle of the ladies-speakers at #EULAR2025 who want to be elegant, professional, but also practical while running from one conference hall to another 🪭🪭👠👟🩴🪭🪭 @rheumnow Ihsane Hmamouchi Avin Maroof Puja Mehta Krystel Aouad Mrinalini Dey Ashima Makol MD

I think that the standards of what « elegant » and « professional » means needs to change in general, but particularly it sounds completely outdated to me that women are expected to wear heals and men expected to wear a tie at conferences Professionalism is a behavior, not an

And this is a wrap! #EULAR2025 in Barcelona was full of excellent science! It was a real joy to meet old friends, make new ones, and report for Dr. John Cush alongside a fantastic faculty! See you all in 2026 in London 🇬🇧

48% of the respondents were worried of side effects for combination MTX + LEF So was I ! My take on the abstracts OP0192 and OP0195 on this topic at #EULAR2025 👇 rheumnow.com/news/methotrex… Dr. John Cush

EULAR 2025 – PsA Panel Discussion x.com/i/broadcasts/1…